What the new credit facility and 2026 outlook mean for Oscar Health

Oscar Health (OSCR) just paired a new US$475 million revolving credit facility with fresh 2026 guidance and full year 2025 results. Together, these provide a clearer view of its balance sheet and earnings ambitions.

The new credit facility and 2026 outlook arrive after a mixed year in the market, with a 7 day share price return of 3.96% but a 30 day share price return decline of 19.09% and a 1 year total shareholder return decline of 15.52%, set against a very large 3 year total shareholder return gain that hints at earlier enthusiasm now being reassessed as investors weigh higher recent losses against the company’s longer track record.

If Oscar Health’s update has you reassessing the sector, it could be a good moment to broaden your watchlist with 25 healthcare AI stocks that might fit different risk and growth profiles.

With Oscar Health trading at US$13.39, sitting below the average analyst price target and coming off a year of revenue growth but wider losses, you have to ask: is there a mispriced opportunity here, or is the market already assuming the 2026 earnings guidance plays out?

Most Popular Narrative: 15.1% Undervalued

Oscar Health’s most followed narrative pegs fair value at about $15.78 per share versus the recent $13.39 close. This frames the stock as modestly undervalued and puts its long term earnings story in focus.

The analysts have a consensus price target of $11.143 for Oscar Health based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $14.0, and the most bearish reporting a price target of just $8.0.

Curious what supports a higher fair value than the average price target? This narrative highlights steady revenue gains, margin repair, and a richer future earnings multiple. The full story sits in how those pieces fit together.

Result: Fair Value of $15.78 (UNDERVALUED)

However, higher claims costs in the ACA market and potential policy changes to premium tax credits could both pressure margins and challenge the bullish earnings path.

Next Steps

Given the mix of optimism and concern in this story, it makes sense to look at the numbers yourself and decide quickly how you feel about Oscar Health. You can start with 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Oscar Health is on your radar, do not stop there, use the screener to spot other opportunities that might fit your style before the market prices them differently.

• Spot potential value opportunities early by scanning our 56 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect them yet.
• Prioritise resilience by checking out 80 resilient stocks with low risk scores that score well on stability and risk, so you can focus on ideas that may better match your risk tolerance.
• Hunt for lesser known stories with screener containing 24 high quality undiscovered gems that have solid fundamentals but attract less attention, so you are not always following the crowd.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.